Amrize (NYSE:AMRZ) & PT Semen Indonesia (Persero) Tbk (OTCMKTS:PSGTY) Critical Comparison

Amrize (NYSE:AMRZ) and PT Semen Indonesia (Persero) Tbk (OTCMKTS:PSGTY) are both basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings for Amrize and PT Semen Indonesia (Persero) Tbk, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amrize	0	7	6	1	2.57
PT Semen Indonesia (Persero) Tbk	0	0	0	0	0.00

Amrize currently has a consensus target price of $59.00, suggesting a potential upside of 10.29%. Given Amrize’s stronger consensus rating and higher possible upside, equities analysts plainly believe Amrize is more favorable than PT Semen Indonesia (Persero) Tbk.

Institutional & Insider Ownership

0.0% of PT Semen Indonesia (Persero) Tbk shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Amrize and PT Semen Indonesia (Persero) Tbk’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amrize	N/A	N/A	N/A
PT Semen Indonesia (Persero) Tbk	N/A	N/A	N/A

Valuation and Earnings

This table compares Amrize and PT Semen Indonesia (Persero) Tbk”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amrize	$11.70 billion	2.53	$1.27 billion	$1.84	29.07
PT Semen Indonesia (Persero) Tbk	N/A	N/A	N/A	$18,720.72	0.00

Amrize has higher revenue and earnings than PT Semen Indonesia (Persero) Tbk. PT Semen Indonesia (Persero) Tbk is trading at a lower price-to-earnings ratio than Amrize, indicating that it is currently the more affordable of the two stocks.

Summary

Amrize beats PT Semen Indonesia (Persero) Tbk on 6 of the 8 factors compared between the two stocks.

About Amrize

Amrize AG focuses on building materials business in North America. The company was incorporated in 2023 and is based in Zug, Switzerland. Amrize AG operates independently of Holcim AG as of June 23, 2025.

About PT Semen Indonesia (Persero) Tbk

PT Semen Indonesia (Persero) Tbk manufactures, packs, and distributes cement in Indonesia and internationally. It operates through Cement Production and Non-Cement Production segments. The company is also involved in limestone and clay mining; cement bag manufacturing; industrial real estate development and building rental; ready-mix concrete and aggregates quarry production; and consulting, mining, trading, transportation, and construction activities. In addition, it engages in the information system, investment, freight forwarding, stevedoring, sea transportation, service logistic management, outsourcing, and building materials businesses, as well as procures public goods and services. The company was formerly known as PT Semen Gresik (Persero) Tbk and changed its name to PT Semen Indonesia (Persero) Tbk in January 2013. PT Semen Indonesia (Persero) Tbk was founded in 1953 and is headquartered in Jakarta Selatan, Indonesia.